Skip to main content

Disable motion

Cabozantinib Development Program

Cabozantinib is a tyrosine kinase inhibitor (TKI) discovered and developed by Exelixis.
Cabozantinib was shown in vitro to inhibit multiple receptor tyrosine kinases (RTK) including VEGFR, MET, and the TAM kinases (TYRO3, AXL, and MER). These receptors are involved in normal and pathologic processes such as tumor angiogenesis, invasiveness, metastasis, and immunomodulation of the tumor microenvironment.
This website includes information on investigational uses of compounds that have not been approved by the U.S. Food and Drug Administration (FDA). Safety and efficacy of investigational compounds and/or investigational uses of approved products have not been established. The information presented should not be construed as a recommendation for use.